- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01203917
Efficacy, Safety, Tolerability of Gefitinib as 1st Line in Caucasian Patients With EGFR Mutation Positive Advanced NSCLC (IFUM)
November 14, 2016 updated by: AstraZeneca
An Open Label, Multicentre, Single Arm Study to Characterise the Efficacy, Safety and Tolerability of Gefitinib 250 mg (IRESSA™) as First Line Treatment in Caucasian Patients, Who Have Epidermal Growth Factor Receptor (EGFR) Mutation Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
This study is carried out to see how Caucasian patients with lung cancer which has EGFR mutation will respond to gefitinib (IRESSA™) as a first line treatment.
Safety data will also be collected and analysed to confirm that treatment with gefitinib is safe and well tolerated.
Study Overview
Status
Completed
Intervention / Treatment
Detailed Description
An Open Label, Multicentre, Single Arm Study to Characterise the Efficacy, Safety and Tolerability of Gefitinib 250 mg (IRESSA™) as First line Treatment in Caucasian Patients, who have Epidermal Growth Factor Receptor (EGFR) Mutation Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Study Type
Interventional
Enrollment (Actual)
1060
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Plovdiv, Bulgaria
- Research Site
-
Sofia, Bulgaria
- Research Site
-
Stara Zagora, Bulgaria
- Research Site
-
Varna, Bulgaria
- Research Site
-
Vratza, Bulgaria
- Research Site
-
-
-
-
-
ANGERS Cedex 9, France
- Research Site
-
Saint Herblain Cedex, France
- Research Site
-
-
-
-
-
Athens, Greece
- Research Site
-
Heraklion, Greece
- Research Site
-
Larissa, Greece
- Research Site
-
Thessaloniki, Greece
- Research Site
-
-
-
-
-
Budapest, Hungary
- Research Site
-
Deszk, Hungary
- Research Site
-
Edelény, Hungary
- Research Site
-
Győr, Hungary
- Research Site
-
Mosdós, Hungary
- Research Site
-
Székesfehérvár, Hungary
- Research Site
-
-
-
-
-
Ancona, Italy
- Research Site
-
Carpi, Italy
- Research Site
-
Livorno, Italy
- Research Site
-
Perugia, Italy
- Research Site
-
-
-
-
-
Oslo, Norway
- Research Site
-
Stavanger, Norway
- Research Site
-
Trondheim, Norway
- Research Site
-
-
-
-
-
Gdańsk, Poland
- Research Site
-
Kraków, Poland
- Research Site
-
Lubin, Poland
- Research Site
-
Olsztyn, Poland
- Research Site
-
Otwock, Poland
- Research Site
-
Szczecin, Poland
- Research Site
-
Toruń, Poland
- Research Site
-
Warszawa, Poland
- Research Site
-
Wrocław, Poland
- Research Site
-
-
-
-
-
Coimbra, Portugal
- Research Site
-
Lisboa, Portugal
- Research Site
-
Porto, Portugal
- Research Site
-
Vila Nova de Gaia, Portugal
- Research Site
-
-
-
-
-
Brasov, Romania
- Research Site
-
Bucharest, Romania
- Research Site
-
Bucuresti, Romania
- Research Site
-
Cluj Napoca, Romania
- Research Site
-
Constanta, Romania
- Research Site
-
-
-
-
-
Lugo, Spain
- Research Site
-
Lérida, Spain
- Research Site
-
Madrid, Spain
- Research Site
-
Majadahonda, Spain
- Research Site
-
Málaga, Spain
- Research Site
-
-
-
-
-
Basel, Switzerland
- Research Site
-
Chur, Switzerland
- Research Site
-
Rapperswil-Jona, Switzerland
- Research Site
-
Sursee, Switzerland
- Research Site
-
-
-
-
-
Ankara, Turkey
- Research Site
-
Istanbul, Turkey
- Research Site
-
Izmir, Turkey
- Research Site
-
-
-
-
-
Aberdeen, United Kingdom
- Research Site
-
Birmingham, United Kingdom
- Research Site
-
Burnley, United Kingdom
- Research Site
-
Cambridge, United Kingdom
- Research Site
-
Dundee, United Kingdom
- Research Site
-
Liverpool, United Kingdom
- Research Site
-
Nottingham, United Kingdom
- Research Site
-
Wolverhampton, United Kingdom
- Research Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 130 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Locally advanced or metastatic non-small cell lung cancer (i.e. cancer that has spread from where it started) which is EGFR mutation positive
- Caucasian female or male patients aged 18 years or over
- Measurable disease, i.e. at least one lesion, not previously irradiated, as ≥ 10 mm in the longest diameter (≥ 15 mm in short axis for lymph node )
Exclusion Criteria:
- Prior adjuvant chemotherapy or other systemic anti-cancer treatment less than 6 month, or palliative radiotherapy less than 4 weeks prior to start of study treatment.
- Brain metastases or spinal cord compression, unless treated and stable without steroids
- Any clinically significant illness, which will jeopardize the patients' safety and their participation in the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: 1
gefitinib 250mg tablet
|
250mg tablet oral, once daily until objective disease progression is documented or until other discontinuation criterion is met
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective Response Rate (ORR) (Investigator)
Time Frame: Scans taken at baseline and then follow up assessments taken every 6 weeks until progression, or last evaluable assessment in the absence of progression, assessed up to 23 months
|
% of patients in the Full analysis set who have a complete response [CR] or partial response [PR] confirmed by repeat imaging at least 4 weeks later with no evidence of progression between confirmation visits (as defined by Response Evaluation Criteria in Solid Tumours version 1.1 (RECIST 1.1)).
CR: disappearance of all target lesions (TLs) & non-target lesions (NTLs).
PR: >= 30% decrease in the sum of diameters compared to baseline (with no evidence of progression) and the NTLs are at least stable with no evidence of new lesions.
Outcome is based on measurements made at site by investigator.
|
Scans taken at baseline and then follow up assessments taken every 6 weeks until progression, or last evaluable assessment in the absence of progression, assessed up to 23 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Disease Control Rate (DCR) (Investigator)
Time Frame: Scans taken at baseline and then follow up assessments taken every 6 weeks until progression, or last evaluable assessment in the absence of progression, assessed up to 23 months
|
DCR is calculated as the % of the FAS patient population with a best visit response of CR, PR (a visit response of CR or PR which is confirmed at least 4 weeks later) or stable disease (SD).
SD is defined as no evidence of CR, PR or progression and must have occurred at a minimum of 6 weeks after first dose of study treatment.
(progression is defined as ≥20% increase in the sum of the diameters of target lesions from minimum; clinically significant progression in non-target lesions; the presence of a new lesion or death).
Outcome is based on measurements made at site by investigator.
|
Scans taken at baseline and then follow up assessments taken every 6 weeks until progression, or last evaluable assessment in the absence of progression, assessed up to 23 months
|
Progression - Free Survival (PFS) (Investigator)
Time Frame: Scans taken at baseline and then follow up assessments taken every 6 weeks until progression, or last evaluable assessment in the absence of progression, assessed up to 23 months
|
PFS was defined as the time from the first dose of gefitinib study treatment until objective disease progression as defined by RECIST 1.1 (≥20% increase in the sum of the diameters of target lesions from minimum, clinically significant progression in non-target lesions or the presence of a new lesion) or death (by any cause in the absence of progression).
Progression is based on measurements made at site by investigator.
|
Scans taken at baseline and then follow up assessments taken every 6 weeks until progression, or last evaluable assessment in the absence of progression, assessed up to 23 months
|
Overall Survival (OS)
Time Frame: Survival follow up from first dose of gefitinib till death of the patient or till end of study in absence of death.
|
OS was defined as the time from first dose of gefitinib study treatment until death by any cause.
Patients who had not died at the time of analysis were censored at the last date the patient was known to be alive.
|
Survival follow up from first dose of gefitinib till death of the patient or till end of study in absence of death.
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Disease Control Rate (DCR) (Independent Central Review)
Time Frame: Scans taken at baseline and then follow up assessments taken every 6 weeks until progression, or last evaluable assessment in the absence of progression, assessed up to 23 months
|
DCR is calculated as the % of the FAS patient population with a best visit response of CR, PR (a visit response of CR or PR which is confirmed at least 4 weeks later) or stable disease (SD).
SD is defined as no evidence of CR, PR or progression and must have occurred at a minimum of 6 weeks after first dose of study treatment.
(progression is defined as ≥20% increase in the sum of the diameters of target lesions from minimum; clinically significant progression in non-target lesions; the presence of a new lesion or death).
Outcome is based on measurements of scans by central review.
|
Scans taken at baseline and then follow up assessments taken every 6 weeks until progression, or last evaluable assessment in the absence of progression, assessed up to 23 months
|
Objective Response Rate (ORR) (Independent Central Review))
Time Frame: Scans taken at baseline and then follow up assessments taken every 6 weeks until progression, or last evaluable assessment in the absence of progression, assessed up to 23 months
|
% of patients in the Full analysis set who have a complete response [CR] or partial response [PR] confirmed by repeat imaging at least 4 weeks later with no evidence of progression between confirmation visits (as defined by Response Evaluation Criteria in Solid Tumours version 1.1 (RECIST 1.1)).
CR: disappearance of all target lesions (TLs) & non-target lesions (NTLs).
PR: >= 30% decrease in the sum of diameters compared to baseline (with no evidence of progression) and the NTLs are at least stable with no evidence of new lesions.
Outcome is based on measurements of scans by central review.
|
Scans taken at baseline and then follow up assessments taken every 6 weeks until progression, or last evaluable assessment in the absence of progression, assessed up to 23 months
|
Progression - Free Survival (PFS) (Independent Central Review)
Time Frame: Scans taken at baseline and then follow up assessments taken every 6 weeks until progression, or last evaluable assessment in the absence of progression, assessed up to 23 months
|
PFS was defined as the time from the first dose of gefitinib study treatment until objective disease progression as defined by RECIST 1.1 (≥20% increase in the sum of the diameters of target lesions from minimum, clinically significant progression in non-target lesions or the presence of a new lesion) or death (by any cause in the absence of progression).
Progression is based on measurements of scans by central review.
|
Scans taken at baseline and then follow up assessments taken every 6 weeks until progression, or last evaluable assessment in the absence of progression, assessed up to 23 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Haiyi Jiang, AstraZeneca
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2010
Primary Completion (Actual)
August 1, 2012
Study Completion (Actual)
June 1, 2016
Study Registration Dates
First Submitted
September 7, 2010
First Submitted That Met QC Criteria
September 15, 2010
First Posted (Estimate)
September 17, 2010
Study Record Updates
Last Update Posted (Estimate)
January 2, 2017
Last Update Submitted That Met QC Criteria
November 14, 2016
Last Verified
November 1, 2016
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- D791AC00014
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Caucasian Patients With EGFR Mutation Positive Advanced NSCLC
-
AstraZenecaCompletedLocally Advanced or Metastatic EGFR(+) NSCLC PatientsChina
-
Henan Cancer HospitalUnknownAdvanced NSCLC With EGFR MutationChina
-
AstraZenecaNo longer available
-
Astellas Pharma Global Development, Inc.WithdrawnSubjects With NSCLC With an EGFR Activating Mutation
-
PfizerRecruitingEGFR Mutation-positive Inoperable or Reccrent NSCLCJapan
-
Yongchang ZhangRecruitingHER2 Insertion Mutation Positive Advanced NSCLCChina
-
Centre Francois BaclesseHoffmann-La Roche; Groupe Francais De Pneumo-CancerologieTerminatedNSCLC Patients With EGFR Activating MutationFrance
-
AstraZenecaCompletedEGFR Mutation Status in aNSCLC Patients (Locally Advanced and/or Metastatic Disease) With Adenocarcinoma and Non-adenocarcinoma Histologies.Italy, Spain, United Kingdom, Sweden, Japan, Netherlands, Germany, France
-
Centre Francois BaclesseGFPCRecruitingALK Gene Rearrangement Positive | NSCLC Stage IV | NSCLC Stage IIIB | EGFR Gene Mutation | ROS1 Gene MutationFrance
-
Astellas Pharma IncTerminatedEGFR-TKI-naïve Patients With NSCLC Harboring EGFR Activating MutationsJapan
Clinical Trials on Gefitinib
-
Sun Yat-sen UniversityUnknown
-
Qilu Pharmaceutical Co., Ltd.UnknownNon-small-cell Lung CancerChina
-
Sun Yat-sen UniversityWu Jieping Medical FoundationCompletedNon-small Cell Lung CancerChina
-
Jiangsu Famous Medical Technology Co., Ltd.UnknownNon-small Cell Lung Cancer
-
AstraZenecaCompletedNeoplasms, Squamous CellUnited States, Czech Republic, Poland, Germany, Belgium, Taiwan, India, Serbia
-
Anhui Medical UniversityUnknownSelf Efficacy | Drug ToxicityChina
-
NCIC Clinical Trials GroupCompletedProstate CancerCanada
-
University of Maryland, BaltimoreNational Cancer Institute (NCI); University of Maryland Greenebaum Cancer CenterCompleted
-
Samsung Medical CenterUnknownNon-small Cell Lung CancerKorea, Republic of
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedOvarian Cancer | Primary Peritoneal Cavity CancerUnited States, Canada, United Kingdom, Australia